BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 24091716)

  • 21. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.
    Li DL; Chen XR; Ma SX; Chen LK
    Thorac Cancer; 2016 Sep; 7(5):619-622. PubMed ID: 27766783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
    Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
    Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM; Bepler G
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
    Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
    Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A; Wood K; Salgia R
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
    Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
    Cameron L; Solomon B
    Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
    Awad MM; Shaw AT
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):429-39. PubMed ID: 25322323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical Efficacy of Crizotinib in Advanced ALK Positive 
Non-small Cell Lung Cancer].
    Zhao J; Zhang K; Zhang L; Wang H
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M; Wynes MW; Hirsch FR
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
    Chen Z; Akbay E; Mikse O; Tupper T; Cheng K; Wang Y; Tan X; Altabef A; Woo SA; Chen L; Reibel JB; Janne PA; Sharpless NE; Engelman JA; Shapiro GI; Kung AL; Wong KK
    Clin Cancer Res; 2014 Mar; 20(5):1204-1211. PubMed ID: 24327273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of crizotinib in NSCLC patients.
    Hamilton G; Rath B; Burghuber O
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):835-42. PubMed ID: 25732197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Crystal AS; Shaw AT
    Clin Cancer Res; 2012 Sep; 18(17):4479-81. PubMed ID: 22912388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
    Seto T; Kiura K; Nishio M; Nakagawa K; Maemondo M; Inoue A; Hida T; Yamamoto N; Yoshioka H; Harada M; Ohe Y; Nogami N; Takeuchi K; Shimada T; Tanaka T; Tamura T
    Lancet Oncol; 2013 Jun; 14(7):590-8. PubMed ID: 23639470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA; Velez M; Raez LE; Santos ES
    Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.